Abstract
Alzheimers disease (AD) is a heterogeneous and progressive neurodegenerative disease which in Western society mainly accounts for clinical dementia. AD has been linked to inflammation and oxidative stress. Neuro-pathological hallmarks are senile plaques, resulting from the accumulation of several proteins and an inflammatory reaction around deposits of amyloid, a fibrillar protein, Aβ, product of cleavage of a much larger protein, the beta-amyloid precursor protein (APP) and neurofibrillary tangles. Inflammation clearly occurs in pathologically vulnerable regions of AD and several inflammatory factors influencing AD development, i.e. environmental factors (pro-inflammatory phenotype) and/or genetic factors (pro-inflammatory genotype) have been described. Irrespective of the source and mechanisms that lead to the generation of reactive oxygen species, mammalian cells have developed highly regulated inducible defence systems, whose cytoprotective functions are essential in terms of cell survival. When appropriately activated, each one of these systems has the possibility to restore cellular homeostasis and rebalance redox equilibrium. Increasing evidence support the notion that reduction of cellular expression and activity of antioxidant proteins and consequent augment of oxidative stress are fundamental causes for ageing processes and neurodegenerative diseases, including AD. The better understanding of different molecular and cellular inflammatory mechanisms is crucial for complete knowledge of AD pathophysiology, hence for its prevention and drug therapy. Accordingly, two lines of preventive therapeutics can be outlined, the first based on anti-inflammatory drugs, the second one on anti-oxidative properties.
Keywords: Alzheimer's disease, curcumin, IL-6, inflammation, oxidative stress
Current Pharmaceutical Design
Title: Immune-Inflammatory Responses and Oxidative Stress in Alzheimers Disease: Therapeutic Implications
Volume: 16 Issue: 6
Author(s): D. Di Bona, G. Scapagnini, G. Candore, L. Castiglia, G. Colonna-Romano, G. Duro, D. Nuzzo, F. Iemolo, D. Lio, M. Pellicano, V. Scafidi, C. Caruso and S. Vasto
Affiliation:
Keywords: Alzheimer's disease, curcumin, IL-6, inflammation, oxidative stress
Abstract: Alzheimers disease (AD) is a heterogeneous and progressive neurodegenerative disease which in Western society mainly accounts for clinical dementia. AD has been linked to inflammation and oxidative stress. Neuro-pathological hallmarks are senile plaques, resulting from the accumulation of several proteins and an inflammatory reaction around deposits of amyloid, a fibrillar protein, Aβ, product of cleavage of a much larger protein, the beta-amyloid precursor protein (APP) and neurofibrillary tangles. Inflammation clearly occurs in pathologically vulnerable regions of AD and several inflammatory factors influencing AD development, i.e. environmental factors (pro-inflammatory phenotype) and/or genetic factors (pro-inflammatory genotype) have been described. Irrespective of the source and mechanisms that lead to the generation of reactive oxygen species, mammalian cells have developed highly regulated inducible defence systems, whose cytoprotective functions are essential in terms of cell survival. When appropriately activated, each one of these systems has the possibility to restore cellular homeostasis and rebalance redox equilibrium. Increasing evidence support the notion that reduction of cellular expression and activity of antioxidant proteins and consequent augment of oxidative stress are fundamental causes for ageing processes and neurodegenerative diseases, including AD. The better understanding of different molecular and cellular inflammatory mechanisms is crucial for complete knowledge of AD pathophysiology, hence for its prevention and drug therapy. Accordingly, two lines of preventive therapeutics can be outlined, the first based on anti-inflammatory drugs, the second one on anti-oxidative properties.
Export Options
About this article
Cite this article as:
Bona Di D., Scapagnini G., Candore G., Castiglia L., Colonna-Romano G., Duro G., Nuzzo D., Iemolo F., Lio D., Pellicano M., Scafidi V., Caruso C. and Vasto S., Immune-Inflammatory Responses and Oxidative Stress in Alzheimers Disease: Therapeutic Implications, Current Pharmaceutical Design 2010; 16 (6) . https://dx.doi.org/10.2174/138161210790883769
DOI https://dx.doi.org/10.2174/138161210790883769 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structural Exploration of Synthetic Chromones as Selective MAO-B Inhibitors: A Mini Review
Combinatorial Chemistry & High Throughput Screening Patent Selections
Recent Patents on Biotechnology Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Choline Alphoscerate (Alpha-Glyceryl-Phosphoryl-Choline) An Old Choline- containing Phospholipid with a Still Interesting Profile As Cognition Enhancing Agent
Current Alzheimer Research Anti-Aggressive, Brain Neurotransmitters and Receptor Binding Study of Fumaria indica in Rodents
Current Psychopharmacology The Ultra High Risk Approach to Define Psychosis Risk
Current Pharmaceutical Design Socio-economic Aspects of Alzheimer's Disease
Current Alzheimer Research Potential Therapeutics for Vascular Cognitive Impairment and Dementia
Current Neuropharmacology Role of Vitamins in Human Health and Nutrition: Sources and Morbidity
Current Nutrition & Food Science Protein Tyrosine Nitration: Role in Aging
Current Aging Science Predictors of Conversion to Dementia of Probable Alzheimer Type in Patients with Mild Cognitive Impairment
Current Alzheimer Research Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Combining Neuropsychological and Structural Neuroimaging Indicators of Conversion to Alzheimers Disease in Amnestic Mild Cognitive Impairment
Current Alzheimer Research How Much Value Would a Treatment for Alzheimer’s Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy
Current Alzheimer Research Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Current Alzheimer Research Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety Scientific Basis for the Use of Indian Ayurvedic Medicinal Plants in the Treatment of Neurodegenerative Disorders: 1. Ashwagandha
Central Nervous System Agents in Medicinal Chemistry The ATP-Binding Cassette Transporter-2 (ABCA2) Overexpression Modulates Sphingosine Levels and Transcription of the Amyloid Precursor Protein (APP) Gene
Current Alzheimer Research Biochemical and Histochemical Comparison of Cholinesterases in Normal and Alzheimer Brain Tissues
Current Alzheimer Research Electroencephalography and Dementia: A Literature Review and Future Perspectives
CNS & Neurological Disorders - Drug Targets